Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
Identifieur interne : 000147 ( Istex/Curation ); précédent : 000146; suivant : 000148Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
Auteurs : Jan Balzarini [Belgique] ; Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; Frank Vandermeer [Pays-Bas] ; Miguel Stevens [Belgique] ; Erik De Clercq [Belgique] ; Herman Egberink [Pays-Bas] ; Marc Van Ranst [Belgique]Source :
- Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 2005.
Abstract
Objectives: Evaluation of a wide variety of pyridine N-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture. Methods: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine N-oxide derivatives was monitored by spectrophotometric analysis. Results and conclusions: A wide variety of pyridine N-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine N-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50–100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine N-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.
Url:
DOI: 10.1093/jac/dki481
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000147
Links to Exploration step
ISTEX:204CE38B08442996116884669633748144B69C3ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</title><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Corresponding author. Tel: +32-16-337352; Fax: +32-16-337340; E-mail: jan.balzarini@rega.kuleuven.ac.be</mods:affiliation><country wicri:rule="url">Belgique</country></affiliation></author><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Vandermeer, Frank" sort="Vandermeer, Frank" uniqKey="Vandermeer F" first="Frank" last="Vandermeer">Frank Vandermeer</name><affiliation wicri:level="1"><mods:affiliation>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Stevens, Miguel" sort="Stevens, Miguel" uniqKey="Stevens M" first="Miguel" last="Stevens">Miguel Stevens</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name><affiliation wicri:level="1"><mods:affiliation>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:204CE38B08442996116884669633748144B69C3A</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1093/jac/dki481</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-SV6PL67X-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000147</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000147</idno><idno type="wicri:Area/Istex/Curation">000147</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Pyridine <hi rend="italic">N</hi>-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</title><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Corresponding author. Tel: +32-16-337352; Fax: +32-16-337340; E-mail: jan.balzarini@rega.kuleuven.ac.be</mods:affiliation><country wicri:rule="url">Belgique</country></affiliation></author><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Vandermeer, Frank" sort="Vandermeer, Frank" uniqKey="Vandermeer F" first="Frank" last="Vandermeer">Frank Vandermeer</name><affiliation wicri:level="1"><mods:affiliation>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Stevens, Miguel" sort="Stevens, Miguel" uniqKey="Stevens M" first="Miguel" last="Stevens">Miguel Stevens</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name><affiliation wicri:level="1"><mods:affiliation>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><affiliation wicri:level="1"><mods:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium;</mods:affiliation><country xml:lang="fr" wicri:curation="lc">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title><title level="j" type="abbrev">J. Antimicrob. Chemother.</title><idno type="ISSN">0305-7453</idno><idno type="eISSN">1460-2091</idno><imprint><publisher>Oxford University Press</publisher><date type="e-published">2005</date><date type="published">2006</date><biblScope unit="vol">57</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="472">472</biblScope><biblScope unit="page" to="481">481</biblScope></imprint><idno type="ISSN">0305-7453</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0305-7453</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives: Evaluation of a wide variety of pyridine N-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture. Methods: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine N-oxide derivatives was monitored by spectrophotometric analysis. Results and conclusions: A wide variety of pyridine N-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine N-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50–100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine N-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000147 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000147 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:204CE38B08442996116884669633748144B69C3A
|texte= Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
}}
| This area was generated with Dilib version V0.6.33. |  |